{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:28:57Z","timestamp":1780522137102,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s13318-023-00829-5","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T10:36:35Z","timestamp":1684146995000},"page":"329-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT\/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera\u00ae) Case"],"prefix":"10.1007","volume":"48","author":[{"given":"Anissa","family":"Barakat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lore","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrtille","family":"Vivien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Kotzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-8461","authenticated-orcid":false,"given":"Sonia","family":"Khier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"829_CR1","doi-asserted-by":"crossref","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. Multidisciplinary Digital Publishing Institute; 2019;12:114.","DOI":"10.3390\/ph12030114"},{"key":"829_CR2","doi-asserted-by":"crossref","unstructured":"Pouget J-P, Santoro L, Piron B, Paillas S, Ladjohounlou R, Pichard A, et al. From the target cell theory to a more integrated view of radiobiology in targeted radionuclide therapy: The Montpellier group\u2019s experience. Nucl Med Biol. 2021;104\u2013105.","DOI":"10.1016\/j.nucmedbio.2021.11.005"},{"key":"829_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/RLU.0b013e3182814ac1","volume":"38","author":"SK Gupta","year":"2013","unstructured":"Gupta SK, Singla S, Thakral P, Bal CS. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE. Clin Nucl Med. 2013;38:188\u201394.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"829_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"829_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","volume":"54","author":"A Sabet","year":"2013","unstructured":"Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, P\u00f6ppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857\u201361.","journal-title":"J Nucl Med"},{"key":"829_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau F-A, Arsenault F, Saighi N, Bouchard L-O, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundl\u00f6v","year":"2022","unstructured":"Sundl\u00f6v A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49:3830\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"829_CR8","doi-asserted-by":"crossref","unstructured":"Siebinga H, de Wit-van der Veen BJ, Stokkel MDM, Huitema ADR, Hendrikx JJMA. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review. Theranostics. Ivyspring International Publisher; 2022;12:7804\u201320.","DOI":"10.7150\/thno.77279"},{"key":"829_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"829_CR10","doi-asserted-by":"crossref","unstructured":"Santoro L, Pitalot L, Trauchessec D, Mora-Ramirez E, Kotzki PO, Bardi\u00e8s M, et al. Clinical implementation of PLANET\u00ae Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit\u00ae and OLINDA\/EXM\u00ae V1.0. EJNMMI Res. 2021;11:1.","DOI":"10.1186\/s13550-020-00737-8"},{"key":"829_CR11","first-page":"1245","volume":"43","author":"S Shen","year":"2002","unstructured":"Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med. 2002;43:1245\u201353.","journal-title":"J Nucl Med"},{"key":"829_CR12","unstructured":"PKanalix version 2021R2. Antony, France: Lixoft SAS, 2021. Available from: https:\/\/lixoft.com\/products\/pkanalix\/. Access date: 04\/04\/2022."},{"key":"829_CR13","unstructured":"FDA, Highlights of prescribing information - LUTATHERA - 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf. Access date: 04\/02\/2022."},{"key":"829_CR14","unstructured":"Nolain P, Combet R, Marchionni D, Speth H, Martinez JM, Fabre D. PopkinR: a suite of Shiny applications focused on the pharmacometrics workflow. Poster presented to Population Approach Group Europe (PAGE) meeting. Switzerland, 2018. https:\/\/www.page-meeting.org\/?abstract=8684. Access date: 07\/04\/2023."},{"key":"829_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"829_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"key":"829_CR17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","volume":"60","author":"L Hagmarker","year":"2019","unstructured":"Hagmarker L, Svensson J, Ryd\u00e9n T, van Essen M, Sundl\u00f6v A, Gleisner KS, et al. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60:1406\u201313.","journal-title":"J Nucl Med"},{"key":"829_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-018-0674-1","volume":"58","author":"A Puszkiel","year":"2019","unstructured":"Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E. Evaluation of the interaction of amino acid infusion on 177Lu-dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors. Clin Pharmacokinet. 2019;58:213\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"829_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2967\/jnumed.120.245068","volume":"62","author":"LD Jim\u00e9nez-Franco","year":"2021","unstructured":"Jim\u00e9nez-Franco LD, Glatting G, Prasad V, Weber WA, Beer AJ, Kletting P. Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: an in\u00a0silico analysis for standard and optimized treatment. J Nucl Med. 2021;62:92\u20138.","journal-title":"J Nucl Med"},{"key":"829_CR20","doi-asserted-by":"crossref","unstructured":"Chan Kwong AH-XP, O'Jeanson A and Khier S. Model-informed therapeutic drug monitoring of meropenem in critically ill patients: improvement of the predictive ability of literature models with the PRIOR approach. Eur J Drug Metab Pharmacokinet. 2021 ;46(3):415-426.","DOI":"10.1007\/s13318-021-00681-5"},{"key":"829_CR21","doi-asserted-by":"crossref","unstructured":"Chan Kwong AH-XP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47:431\u201346.","DOI":"10.1007\/s10928-020-09695-z"},{"key":"829_CR22","unstructured":"Lutathera European public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lutathera-epar-public-assessment-report_en.pdf. Accessed on 02 July 2022."},{"issue":"9","key":"829_CR23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2967\/jnumed.119.237818","volume":"61","author":"M Lubberink","year":"2020","unstructured":"Lubberink M, Wilking H, \u00d6st A, Ilan E, Sandstr\u00f6m M, Andersson C, et al. In\u00a0vivo instability of 177 Lu-DOTATATE during peptide receptor radionuclide therapy. J Nucl Med. 2020;61(9):1337\u201340.","journal-title":"J Nucl Med"},{"key":"829_CR24","doi-asserted-by":"crossref","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K. MIRD Pamphlet No. 26: Joint EANM\/MIRD Guidelines for Quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151-62.","DOI":"10.2967\/jnumed.115.159012"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00829-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00829-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00829-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T22:13:06Z","timestamp":1688595186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00829-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00829-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"19 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no financial nor non-financial interests that are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB extracted and collected the data, analyzed the data, analyzed literature, and wrote the initial draft of the manuscript. LS contributed to the literature search, data extraction, and writing of the manuscript. MV supervised the statistical analysis and reviewing the manuscript. POK contributed to reviewing the manuscript. ED contributed to data extraction, provided clinical input, and reviewed the manuscript. SK conceptualized the study, contributed to literature research, supervised the pharmacokinetic analysis, and wrote the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"May be available upon reasonable request from the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}